Net4CGD, Gene Therapy for X-linked Chronic Granulomatous Disease (CGD),  is a large-scale integrating project funded by the European Commission 7th framework programme (FP7) under the call HEALTH.2012.2.4.4-1: Preclinical and/or clinical development of substances with a clear potential as orphan drugs. FP7-HEALTH-2012-INNOVATION-1, for 48 months (Dec 1, 2012 – Nov 30, 2016). The consortium consists of 11 partners and is coordinated by Anne Galy, Genethon. 
This project is focused on the clinical development of a new orphan drug that can rapidly become a new treatment option for patients with the X-linked form of chronic granulomatous disease (X-CGD).

About Orphan Drugs (Eurordis web site)

"Orphan drugs" are medicinal products intended for diagnosis, prevention or treatment of life-threatening or debilitating rare diseases. They are "orphans" because the pharmaceutical industry has little interest under normal market conditions in developing and marketing drugs intended for only a small number of patients suffering from very rare conditions.